Current cancer therapies and their influence on glucose control

查看全文 作　　者：Carly [1]Yim;Kerry [2]Mansell;Nassrein [3]Hussein;Terra [4]Arnason

机构地区：[1]Department of Medicine,University of Saskatchewan,Saskatoon S7N 0W8,Saskatchewan,Canada;[2]College of Pharmacy and Nutrition,University of Saskatchewan,Saskatoon S7N 5E5,Saskatchewan,Canada;[3]Department of Medicine,Division of Endocrinology,University of Saskatchewan,Saskatoon S7N 0W8,Saskatchewan,Canada;[4]Departments of Anatomy and Cell Biology and Medicine,Division of Endocrinology,University of Saskatchewan,Saskatoon S7N 0W8,Saskatchewan,Canada

出　　处：《World Journal of Diabetes》索引2021年第12卷第7期,共16页

摘　　要：This review focuses on the development of hyperglycemia arising from widely used cancer therapies spanning four drug classes.These groups of medications were selected due to their significant association with new onset hyperglycemia,or of potentially severe clinical consequences when present.These classes include glucocorticoids that are frequently used in addition to chemotherapy treatments,and the antimetabolite class of 5-fluorouracil-related drugs.Both of these classes have been in use in cancer therapy since the 1950s.Also considered are the phosphatidyl inositol-3-kinase(PI3K)/AKT/mammalian target of rapamycin(mTOR)-inhibitors that provide cancer response advantages by disrupting cell growth,proliferation and survival signaling pathways,and have been in clinical use as early as 2007.The final class to be reviewed are the monoclonal antibodies selected to function as immune checkpoint inhibitors(ICIs).These were first used in 2011 for advanced melanoma and are rapidly becoming widely utilized in many solid tumors.For each drug class,the literature has been reviewed to answer relevant questions about these medications related specifically to the characteristics of the hyperglycemia that develops with use.The incidence of new glucose elevations in euglycemic individuals,as well as glycemic changes in those with established diabetes has been considered,as has the expected onset of hyperglycemia from their first use.This comparison emphasizes that some classes exhibit very immediate impacts on glucose levels,whereas other classes can have lengthy delays of up to 1 year.A comparison of the spectrum of severity of hyperglycemic consequences stresses that the appearance of diabetic ketoacidosis is rare for all classes except for the ICIs.There are distinct differences in the reversibility of glucose elevations after treatment is stopped,as the mTOR inhibitors and ICI classes have persistent hyperglycemia long term.These four highlighted drug categories differ in their underlying mechanisms driving hyperglycemia,with clinical presentations ranging from potent yet transient insulin resistant states[type 2 diabetes mellitus(T2DM)-like]to rare permanent insulin-deficient causes of hyperglycemia.Knowledge of the relative incidence of new onset hyperglycemia and the underlying causes are critical to appreciate how and when to best screen and treat patients taking any of these cancer drug therapies. 关键词：Cancer therapy HYPERGLYCEMIA adverse drug effects Immune checkpoint inhibitors mTOR inhibitors 5-fluorouracil analogs GLUCOCORTICOIDS Diabetes mellitus

相关文献

参考文献（107）
引证文献（6）
耦合文献（31）

参考文献(107)

引证文献(6)

耦合文献(31)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Current cancer therapies and their influence on glucose control

参考文献(107)

引证文献(6)

耦合文献(31)

用户提示